Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors

PURPOSE: Although EGF receptor tyrosine kinase inhibitors (EGFR-TKI) have shown dramatic effects against EGFR mutant lung cancer, patients ultimately develop resistance by multiple mechanisms. We therefore assessed the ability of combined treatment with the Met inhibitor crizotinib and new generatio...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Nanjo, Shigeki, Yamada, Tadaaki, Nishihara, Hiroshi, Takeuchi, Shinji, Sano, Takako, Nakagawa, Takayuki, Ishikawa, Daisuke, Zhao, Lu, Ebi, Hiromichi, Yasumoto, Kazuo, Matsumoto, Kunio, Yano, Seiji
פורמט: Artigo
שפה:Inglês
יצא לאור: Public Library of Science 2013
נושאים:
Research Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3873434/
https://ncbi.nlm.nih.gov/pubmed/24386407
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0084700
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים